NCT04983888View on ClinicalTrials.gov

Obinutuzumab in Primary FSGS

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions

Primary Focal Segmental Glomerulosclerosis

Interventions

DRUG

Obinutuzumab

1g IV on day one and 1 g IV on day 15, followed by identical course at month 6

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER